JM, H., J, M., H, K., J, F., J, S., JK, S., . . . S, B. (2026). MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay. Blood, 147(19), 2194. https://doi.org/10.1182/blood.2025031089
Chicago Style (17th ed.) CitationJM, Heger, et al. "MRD-2 in the GHSG HD21 Trial Assessed by a Validated Circulating Tumor DNA Sequencing Assay." Blood 147, no. 19 (2026): 2194. https://doi.org/10.1182/blood.2025031089.
MLA (9th ed.) CitationJM, Heger, et al. "MRD-2 in the GHSG HD21 Trial Assessed by a Validated Circulating Tumor DNA Sequencing Assay." Blood, vol. 147, no. 19, 2026, p. 2194, https://doi.org/10.1182/blood.2025031089.
Warning: These citations may not always be 100% accurate.
